EAN 2021 | Diagnosing Alzheimer’s disease using blood-based biomarkers

Charlotte Teunissen • 4 Jun 2021

EAN 2021

Amyloid beta and tau deposition are widely used biomarkers for Alzheimer’s diagnosis that reflect the underlying disease pathology. Changes in these proteins in cerebral spinal fluid or amyloid-PET can confirm the presence of Alzheimer’s. Charlotte Teunissen, PhD, VU University Medical Center, Amsterdam, The Netherlands, talks on recent technological developments that have enabled the measurement of amyloid and tau in the blood. Strong data supporting the reliability of these serum biomarkers has been published recently, meaning they may represent a rapid, non-invasive, and low-cost tool for Alzheimer’s diagnosis and screening. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Research of Prof. Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association.
Prof. Teunissen is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.
Prof. Teunissen has a collaboration contract with ADx Neurosciences and Quanterix, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon.